Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-06-Speech-2-355"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-09-06"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products for paediatric use2
dcterms:Language	"sv"^^xsd:language2
lpv:document identification number	"en.20050906.36.2-355"2
lpv:hasSubsequent	lp_eu:2005-09-06-Speech-2-3562
lpv:speaker	lp:Carl Schlyter2
lpv:spokenAs	member; Delegation to the ACP-EU Joint Parliamentary Assembly (2004-09-15--2009-07-13)3 substitute; CONT (2004-07-21--2007-01-14)3 member; G/EFA (2004-07-20--2009-07-13)3 member; ENVI (2004-07-21--2007-01-14)3 unknown; Miljöpartiet (2004-07-20--2009-07-13)3 substitute; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2004-09-15--2007-03-13)3 substitute; PECH (2004-07-21--2007-01-14)3
lpv:translated text	"Mr President, children must have safe medicines, adapted to their needs. That is an obvious requirement of legislation. With a patent extension as long as six months, we are, however, paying an unnecessarily high price for having the pharmaceutical companies fulfil obvious requirements. The pharmaceutical companies already have multiannual protection and EUR 100 billion in their coffers for purchases. They can tolerate a 1% increase in costs much better than already depleted public budgets. We must not transfer even more money to these companies. In doing so, we should finally end up with safe medicines for both children and adults, but with no one able to afford them. We in the Group of the Greens/European Free Alliance have put forward a compromise amendment involving a maximum of four months, with the further limitations described by Mrs Breyer. If this is unacceptable, Parliament will show that it is more attentive to the pharmaceutical companies’ lobbyists than to the needs of children."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph